Gain Therapeutics Inc (GANX)
$2.79
+0.09
(+3.33%)▲
Live
Performance
- $2.63$2.82$2.79
5.73%
Downside
Day's Volatility :6.86%
Upside
1.19%
- $0.89$5.33$2.79
68.1%
Downside
52 Weeks Volatility :83.3%
Upside
47.65%
Returns
| Period | Gain Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 132.76% | 0.0% |
6 Months | -14.83% | 0.0% |
1 Year | -10.6% | 0.0% |
3 Years | -62.18% | -23.0% |
Highlights
Market Capitalization | 70.7M |
Book Value | $0.47 |
Earnings Per Share (EPS) | -1.31 |
Wall Street Target Price | 6.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -72.96% |
Return On Equity TTM | -188.83% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -7.7M |
EBITDA | -21.8M |
Diluted Eps TTM | -1.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.89 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 141.94%
Technicals Summary
Sell
Neutral
Buy
Gain Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Gain Therapeutics Inc | 74.19% | -14.83% | -10.6% | -62.18% | -75.89% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Gain Therapeutics Inc | NA | NA | NA | -1.05 | -1.89 | -0.73 | NA | 0.47 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Gain Therapeutics Inc | Buy | $70.7M | -75.89% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Gain Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 93.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 107.0%
Institutional Holdings
Timelo Investment Management Inc.
2.37%Alyeska Investment Group, L.P.
1.76%HOHIMER WEALTH MANAGEMENT, LLC
1.29%Geode Capital Management, LLC
0.72%Vanguard Group Inc
0.57%Cable Car Capital LLC
0.57%
Company Information
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
Organization | Gain Therapeutics Inc |
Employees | 29 |
CEO | Dr. Khalid Islam Ph.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.79
+3.33%
Invesco Bulletshares 2025 Hi
$2.79
+3.33%
Schwab International Dividend Equity Etf
$2.79
+3.33%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.79
+3.33%
Lightpath Technologies Inc
$2.79
+3.33%
Vaneck Vectors Global Alternative Energy Etf
$2.79
+3.33%
First Trust Flexible Municipal High Income Etf
$2.79
+3.33%
Drx Dly Reg Bank Bull 3x
$2.79
+3.33%
Graniteshares 2x Long Pltr Daily Etf
$2.79
+3.33%